Cambridge Biotherapies™, a leader in advanced mental health treatments, has launched Spravato™ (esketamine) nasal spray therapy at its Beverly center. This innovative treatment offers rapid relief for patients with treatment-resistant depression. Covered by most insurance providers, Spravato™ is set to expand to other Cambridge Biotherapies locations in the coming months. The therapy is administered under professional supervision in a supportive environment, providing an accessible alternative to IV ketamine therapy.
Founder and Medical Director, Dr. Daniel Brenner, highlights the significance of Spravato by saying, “Spravato™ represents a significant advancement in our ability to treat severe depression affordably. It’s common to see remarkable improvements in patients who previously had few options. We are thrilled to offer this life-changing therapy to our community.” Patients begin their journey with a thorough evaluation to determine eligibility and set goals. The nasal spray is self-administered in a clinical setting, followed by a two-hour monitoring period for safety and effectiveness.
Cambridge Biotherapies currently offers Spravato™ therapy at its Beverly and Cambridge locations, with plans to expand to Amherst by early Fall 2024. Each center is staffed by specialists trained in compassionate care, ensuring the highest level of support. Ongoing follow-up appointments help integrate the therapeutic benefits into daily life. Led by Harvard-trained psychiatrist Dr. Daniel Brenner, Cambridge Biotherapies is committed to innovative mental health care and transforming lives across Massachusetts.
